Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
Identifieur interne : 000760 ( Main/Exploration ); précédent : 000759; suivant : 000761Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
Auteurs : Shashi Gujar [Canada] ; Jonathan G. Pol [France] ; Youra Kim [Canada] ; Guido Kroemer [France, République populaire de Chine, Suède]Source :
- Oncoimmunology [ 2162-4011 ] ; 2020.
Abstract
The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.
DOI: 10.1080/2162402X.2020.1794424
PubMed: 32923158
PubMed Central: PMC7458627
Affiliations:
- Canada, France, République populaire de Chine, Suède
- Svealand, Île-de-France
- Paris, Stockholm, Villejuif
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing CD8<sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?</title><author><name sortKey="Gujar, Shashi" sort="Gujar, Shashi" uniqKey="Gujar S" first="Shashi" last="Gujar">Shashi Gujar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Biology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Beatrice Hunter Cancer Research Institute, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Pol, Jonathan G" sort="Pol, Jonathan G" uniqKey="Pol J" first="Jonathan G" last="Pol">Jonathan G. Pol</name><affiliation wicri:level="3"><nlm:affiliation>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Kim, Youra" sort="Kim, Youra" uniqKey="Kim Y" first="Youra" last="Kim">Youra Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="3"><nlm:affiliation>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut Universitaire de France, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Universitaire de France, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou</wicri:regionArea><wicri:noRegion>Suzhou</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32923158</idno><idno type="pmid">32923158</idno><idno type="doi">10.1080/2162402X.2020.1794424</idno><idno type="pmc">PMC7458627</idno><idno type="wicri:Area/Main/Corpus">000134</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000134</idno><idno type="wicri:Area/Main/Curation">000134</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000134</idno><idno type="wicri:Area/Main/Exploration">000134</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Repurposing CD8<sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?</title><author><name sortKey="Gujar, Shashi" sort="Gujar, Shashi" uniqKey="Gujar S" first="Shashi" last="Gujar">Shashi Gujar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Biology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Beatrice Hunter Cancer Research Institute, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Pol, Jonathan G" sort="Pol, Jonathan G" uniqKey="Pol J" first="Jonathan G" last="Pol">Jonathan G. Pol</name><affiliation wicri:level="3"><nlm:affiliation>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Kim, Youra" sort="Kim, Youra" uniqKey="Kim Y" first="Youra" last="Kim">Youra Kim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="3"><nlm:affiliation>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><placeName><settlement type="city">Villejuif</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut Universitaire de France, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Universitaire de France, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou</wicri:regionArea><wicri:noRegion>Suzhou</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author></analytic><series><title level="j">Oncoimmunology</title><idno type="ISSN">2162-4011</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8<sup>+</sup> T cells for cancer immunotherapy strategies.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32923158</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2162-4011</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Oncoimmunology</Title><ISOAbbreviation>Oncoimmunology</ISOAbbreviation></Journal><ArticleTitle>Repurposing CD8<sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?</ArticleTitle><Pagination><MedlinePgn>1794424</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/2162402X.2020.1794424</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8<sup>+</sup> T cells for cancer immunotherapy strategies.</AbstractText><CopyrightInformation>© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gujar</LastName><ForeName>Shashi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pol</LastName><ForeName>Jonathan G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Youra</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroemer</LastName><ForeName>Guido</ForeName><Initials>G</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9334-4405</Identifier><AffiliationInfo><Affiliation>Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Universitaire de France, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncoimmunology</MedlineTA><NlmUniqueID>101570526</NlmUniqueID><ISSNLinking>2162-4011</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD8+ T cell epitopes</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antigen spreading</Keyword><Keyword MajorTopicYN="N">antiviral immunity</Keyword><Keyword MajorTopicYN="N">cancer immunotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32923158</ArticleId><ArticleId IdType="doi">10.1080/2162402X.2020.1794424</ArticleId><ArticleId IdType="pii">1794424</ArticleId><ArticleId IdType="pmc">PMC7458627</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation><ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunother Cancer. 2020 Feb;8(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">32102830</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Apr;26(4):453-455</Citation><ArticleIdList><ArticleId IdType="pubmed">32284614</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Jun 25;181(7):1489-1501.e15</Citation><ArticleIdList><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2020 Feb;20(2):75-76</Citation><ArticleIdList><ArticleId IdType="pubmed">31925406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Immunol. 2020 Jun 26;5(48):</Citation><ArticleIdList><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2020 Apr;38(4):420-425</Citation><ArticleIdList><ArticleId IdType="pubmed">32042168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2014 Jul 1;74(13):3466-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24795429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2020 Jun;20(6):353</Citation><ArticleIdList><ArticleId IdType="pubmed">32355329</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncoimmunology. 2018 Aug 27;7(12):e1503032</Citation><ArticleIdList><ArticleId IdType="pubmed">30524901</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2018 Sep 19;10(459):</Citation><ArticleIdList><ArticleId IdType="pubmed">30232229</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2019 Feb 4;10(1):567</Citation><ArticleIdList><ArticleId IdType="pubmed">30718505</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2019 Feb 21;176(5):1240-1240.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">30794777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2007 Apr;15(4):651-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17299401</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2018 Mar;39(3):209-221</Citation><ArticleIdList><ArticleId IdType="pubmed">29275092</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Cell Mol Biol. 2018;341:201-276</Citation><ArticleIdList><ArticleId IdType="pubmed">30262033</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 May 29;368(6494):1012-1015</Citation><ArticleIdList><ArticleId IdType="pubmed">32303590</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2020 Jun 1;217(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">32353870</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2005 Mar 1;105(5):1898-904</Citation><ArticleIdList><ArticleId IdType="pubmed">15542583</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>France</li><li>République populaire de Chine</li><li>Suède</li></country><region><li>Svealand</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Stockholm</li><li>Villejuif</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Gujar, Shashi" sort="Gujar, Shashi" uniqKey="Gujar S" first="Shashi" last="Gujar">Shashi Gujar</name></noRegion><name sortKey="Gujar, Shashi" sort="Gujar, Shashi" uniqKey="Gujar S" first="Shashi" last="Gujar">Shashi Gujar</name><name sortKey="Gujar, Shashi" sort="Gujar, Shashi" uniqKey="Gujar S" first="Shashi" last="Gujar">Shashi Gujar</name><name sortKey="Gujar, Shashi" sort="Gujar, Shashi" uniqKey="Gujar S" first="Shashi" last="Gujar">Shashi Gujar</name><name sortKey="Kim, Youra" sort="Kim, Youra" uniqKey="Kim Y" first="Youra" last="Kim">Youra Kim</name></country><country name="France"><region name="Île-de-France"><name sortKey="Pol, Jonathan G" sort="Pol, Jonathan G" uniqKey="Pol J" first="Jonathan G" last="Pol">Jonathan G. Pol</name></region><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><name sortKey="Pol, Jonathan G" sort="Pol, Jonathan G" uniqKey="Pol J" first="Jonathan G" last="Pol">Jonathan G. Pol</name><name sortKey="Pol, Jonathan G" sort="Pol, Jonathan G" uniqKey="Pol J" first="Jonathan G" last="Pol">Jonathan G. Pol</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name></noRegion></country><country name="Suède"><region name="Svealand"><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000760 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000760 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32923158
|texte= Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32923158" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |